Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

Travere Therapeutics (TVTX) reported $81.73 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 97.6%. EPS of -$0.47 for the same period compares to -$1.76 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $79.35 million, representing a surprise of +3.00%. The company delivered an EPS surprise of +14.55%, with the consensus EPS estimate being -$0.55.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Tiopronin products / Thiola: $19.98 million compared to the $20.90 million average estimate based on seven analysts. The reported number represents a change of -0.8% year over year.
• Total net product sales: $75.86 million versus $69.96 million estimated by seven analysts on average.
• Revenue- FILSPARI: $55.88 million compared to the $49.31 million average estimate based on seven analysts. The reported number represents a change of +181.7% year over year.
• Revenue- License and collaboration revenue: $5.87 million versus the seven-analyst average estimate of $4.20 million. The reported number represents a year-over-year change of +322.4%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com